ALLIANCE PHARMA LS-,01

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2023, ALLIANCE PHARMA LS-,01 has already paid €0.0205 in dividends. The last payout was in July 2023.

Financials

In the last year, ALLIANCE PHARMA LS-,01 had revenue of €215.66m and net profit of -€12.94m

(EUR)	2024	YoY
Revenue	215.66m	3.65%
Gross profit	131.79m	8.97%
Net profit	-12.94m	66.09%
EBITDA	4.66m	113.98%

Fundamentals

Metric	Value
Market capitalization	€417.44m
Number of shares	540.57m
52-week high/low	€0.79 - €0.29
Dividends	No
Beta	0.58
P/E ratio	-32.51
PEG ratio	-0.33
P/B ratio	1.68
P/S ratio	1.96

Company profile

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.